General Announcement::Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
17-Jan-2022 13:40:12
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection
Announcement Reference
SG220117OTHR75A9
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
17/01/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe

Attachments

SGX_PR_17012022.pdf
Total size =1300K